Literature DB >> 22326270

Clinical and biological significance of Cdk10 in hepatocellular carcinoma.

Xiang-yu Zhong1, Xiao-xue Xu, Jian-hua Yu, Gui-xing Jiang, Yang Yu, Sheng Tai, Zhi-dong Wang, Yun-fu Cui.   

Abstract

Cyclin-dependent kinase 10 (Cdk10) is a Cdc2-related kinase and plays an essential role in the progression from the G2 to M phase of the cell cycle. However, relative little is known about its expression pattern, clinical relevance, and biological function in hepatocellular carcinoma (HCC). In the present study, we investigated the mRNA and protein expression levels of Cdk10 in 127 pairs of HCC samples and adjacent nontumorous liver tissues and evaluated its clinical significance. Additionally, we assessed the effects of restoration of Cdk10 on cell proliferation and drug sensitivity in HCC cells. We showed that the Cdk10 mRNA and protein expression was markedly decreased in HCC samples compared to adjacent nontumorous liver tissues. Quantitative real-time polymerase chain reaction and immunohistochemical studies revealed that reduced Cdk10 expression was significantly associated with alpha-fetoprotein levels, tumor size, and tumor stage. Ectopic expression of Cdk10 reduced HCC cell proliferation, blocked the cell cycle at the G0-G1 phase, as well as inhibited cell migration and anchorage-independent growth. Additionally, Cdk10 overexpression enhanced the chemosensitivity of HCC cells to cisplatin and epidoxorubicin, two chemotherapeutic agents commonly used in HCC. These data collectively demonstrate that reduced Cdk10 expression is closely linked to HCC development and progression. Restoration of its expression may have therapeutic benefits in treating this malignancy.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22326270     DOI: 10.1016/j.gene.2012.01.022

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  13 in total

1.  Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report.

Authors:  Yanjie You; Haijun Li; Xin Qin; Yinpo Zhang; Wengang Song; Yonggang Ran; Fenglan Gao
Journal:  Cell Oncol (Dordr)       Date:  2015-09-21       Impact factor: 6.730

2.  miR-433 accelerates acquired chemoresistance of gallbladder cancer cells by targeting cyclin M.

Authors:  Jianhua Yu; Weiguang Zhang; Baochun Lu; Hongwei Qian; Haijun Tang; Zhiyang Zhu; Xinggui Yuan; Peitu Ren
Journal:  Oncol Lett       Date:  2017-12-28       Impact factor: 2.967

3.  Knockdown of cyclin-dependent kinase 10 (cdk10) gene impairs neural progenitor survival via modulation of raf1a gene expression.

Authors:  Chi-Wei Yeh; Shoa-Hsuan Kao; Yi-Chuan Cheng; Li-Sung Hsu
Journal:  J Biol Chem       Date:  2013-07-31       Impact factor: 5.157

4.  Promoter hypermethylation contributes to the frequent suppression of the CDK10 gene in human nasopharyngeal carcinomas.

Authors:  Yanjie You; Wenjun Yang; Zhizhong Wang; Huimin Zhu; Haijun Li; Canfeng Lin; Yonggang Ran
Journal:  Cell Oncol (Dordr)       Date:  2013-06-06       Impact factor: 6.730

Review 5.  Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.

Authors:  Mitra Zabihi; Ramin Lotfi; Amir-Mohammad Yousefi; Davood Bashash
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-04       Impact factor: 4.553

6.  CDK10/cyclin M is a protein kinase that controls ETS2 degradation and is deficient in STAR syndrome.

Authors:  Vincent J Guen; Carly Gamble; Marc Flajolet; Sheila Unger; Aurélie Thollet; Yoan Ferandin; Andrea Superti-Furga; Pascale A Cohen; Laurent Meijer; Pierre Colas
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

Review 7.  Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.

Authors:  Marion Peyressatre; Camille Prével; Morgan Pellerano; May C Morris
Journal:  Cancers (Basel)       Date:  2015-01-23       Impact factor: 6.639

8.  Low Expression of CDK10 Correlates with Adverse Prognosis in Gastric Carcinoma.

Authors:  Bai-Wei Zhao; Shi Chen; Yuan-Fang Li; Jun Xiang; Zhi-Wei Zhou; Jun-Sheng Peng; Ying-Bo Chen
Journal:  J Cancer       Date:  2017-08-25       Impact factor: 4.207

Review 9.  CDK10 in Gastrointestinal Cancers: Dual Roles as a Tumor Suppressor and Oncogene.

Authors:  Zainab A Bazzi; Isabella T Tai
Journal:  Front Oncol       Date:  2021-06-30       Impact factor: 6.244

10.  Deregulations in the cyclin-dependent kinase-9-related pathway in cancer: implications for drug discovery and development.

Authors:  Gaetano Romano
Journal:  ISRN Oncol       Date:  2013-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.